White piedra (or tinea blanca) is a mycosis of the hair caused by several species of fungi in the genus Trichosporon. It is characterized by soft nodules composed of yeast cells and arthroconidia that encompass hair shafts. Diagnosis
White piedra can occur on the hair of the scalp; Trichosporon ovoides is likely the cause in this case. White piedra on scalp hair is rarely caused by Trichosporon inkin; pubic hair with white piedra is what T. inkin is mainly associated with. White piedra can occur on pubic hair; T. inkin likely causes this.Trichosporon beigelii

Treatment
There are several approaches to treat this infectious disease. One approach involves shaving the affected areas. Another approach involves the use of antifungal medication. See also
Trichobacteriosis axillaris

References
External links

DermAtlas 2062238337
However, this kind of stent may also increase the risk of vascular thrombosis. Vascular malformations
Sirolimus is used to treat vascular malformations. Treatment with sirolimus can decrease pain and the fullness of vascular malformations, improve coagulation levels, and slow the growth of abnormal lymphatic vessels. Sirolimus is a relatively new medical therapy for the treatment of vascular malformations in recent years, sirolimus has emerged as a new medical treatment option for both vascular tumors and vascular malformations, as a mammalian target of rapamycin (mTOR), capable of integrating signals from the PI3K/AKT pathway to coordinate proper cell growth and proliferation. Hence, sirolimus is ideal for "proliferative" vascular tumors through the control of tissue overgrowth disorders caused by inappropriate activation of the PI3K/AKT/mTOR pathway as an antiproliferative agent. Angiofibromas
Sirolimus has been used as a topical treatment of angiofibromas with tuberous sclerosis complex (TSC). Facial angiofibromas occur in 80% of patients with TSC, and the condition is very disfiguring. A retrospective review of English-language medical publications reporting on topical sirolimus treatment of facial angiofibromas found sixteen separate studies with positive patient outcomes after using the drug. The reports involved a total of 84 patients, and improvement was observed in 94% of subjects, especially if treatment began during the early stages of the disease. Sirolimus treatment was applied in several different formulations (ointment, gel, solution, and cream), ranging from 0.003 to 1% concentrations.